Advanced Solid Tumor
Conditions
Brief summary
This is an open label, multi-cohort, multicenter Phase II study, the purpose of this study is to assess the efficacy and safety of envofolimab in combination with BD0801 injection with/without chemotherapy for the treatment of advanced solid tumors
Detailed description
The efficacy of immune checkpoint inhibitors combined with antivascular agents has been preliminarily demonstrated in a variety of solid tumors. Based on the huge clinical needs, the efficacy of envofolimab combined with BD0801 in patients with advanced hepatocellular carcinoma, non-small cell lung cancer and advanced colorectal cancer deserves further exploration.
Interventions
DRUGEnvofolimab
300mg，Q3W (arm A,B and C)or 200mg, Q2W(arm D)
DRUGBD0801
2mg/kg，Q3W(armA, B and C) or 2mg/kg，Q2W
DRUGDocetaxel
75mg/m2，Q3W
DRUGIrinotecan
180 mg/m2，Q2W
DRUGLeucovorin calcium
400mg/m2，Q2W
DRUG5-Fluorouridine
2400 mg/m2，Q2W
Sponsors
Jiangsu Simcere Pharmaceutical Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients voluntarily signed informed consent; 2. Age≥18 age years old, male or female; 3. Patients diagnosed with unresectable or advanced solid tumors confirmed by histopathology or cytology; Cohort A: Patients must have progressed on standard of therapy, patients with NSCLC, CRC and HCC (include intrahepatic cholangiocarcinoma or mixed hepatocellular carcinoma-cholangiocarcinoma in safety run-in phase) are enrolled preferentially; Cohort B: Patients with histopathologically or cytologically or clinically diagnosed advanced HCC (Barcelona Clinic Liver Cancer (BCLC) Stage C; or BCLC Stage B patients who are not suitable for locoregional therapy (such as TACE) may also be enrolled), Child-Pugh liver function grade A and patients received at least one standard first-line systemic treatment and no more than 3 systemic regimens for HCC; Cohort C: Histologically confirmed NSCLC (except for patients with central and cavernous lung squamous cell carcinoma). Patients received at least one standard first line systemic treatment are required, if patients with EGFR、ALK or ROS1 gene positive, first line of target therapy will be required ( if patients with known EGFR mutation, they should be T790M negative or with osimertinib treatment failure); C1: Required prior anti-PD-1/PD-L1 therapy. C2: Never used prior anti-PD-1/PD-L1 therapy. Cohort D: Patients with advanced CRC confirmed with histology, the results of tissue samples must meet any of the following (1. the test result of immunohistochemistry is mismatch repair protein integrity (pMMR) 2. the test result of NGS is MSI-L or MSS 3 the test of result of PCR is MSI-L or MSS). Has received the oxaliplatin and 5-Fu containing regimen for the treatment of metastatic tumors. 4. ECOG score 0 or 1; 5. At least one measurable lesion as per RECIST V1.1; 6. Normal major organ and marrow functions as defined and no blood transfusion and blood product within 2 weeks before screening, no use of hematopoietic stimulating factors; 7. Life expectancy≥12 weeks; 8. Women of childbearing potential must have a negative blood pregnancy test within 7 days prior to the first dose. Male or female patients of childbearing potential voluntarily use effective contraceptive methods from signing the informed consent form to 6 months after initiation of the study drug, such as double-barrier contraceptive methods, condoms, oral or injectable contraceptives, intrauterine devices, etc. All female patients are considered to be of childbearing potential unless they are postmenopausal (continuous menopause for 12 month), had undergone artificial menopause, or had undergone surgical sterilization (e.g., hysterectomy, surgical adnexectomy);
Exclusion criteria
1. Patients who have participated in clinical trials of other investigational drugs or investigational devices within 28 days prior to the first dose or received any systemic treatments within 2 weeks, include but not limited chemotherapy, radiotherapy (palliative radiotherapy is allowed at least 1 week before the study drug treatment), targeted therapy, Chinese herbal medicine or proprietary Chinese medicine for cancer control; 2. Patients with a history of Envofolimab or BD0801 treatment; 3. Patients who have ascites requiring drainage or diuretic treatment or pleural effusion or pericardial effusion requiring drainage and/or accompanied by shortness of breath within 2 weeks before the first dose of study drug treatment; 4. Cholangiocarcinoma, mixed cell carcinoma, or fibroblastic layer cell carcinoma are known for Cohort B; 5. Patients with other active malignancies within 2 years prior to the first administration of the study drug randomization, curable localized tumors, such as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical carcinoma in situ, and carcinoma in situ of the breast can be included in the group; 6. Patients whose toxicity and side effects (due to previous anticancer treatments) have not recovered to≤grade 1, unless such AE is not considered to pose safety risks (such as hair loss and neuropathy≤grade 2 caused by oxaliplatin) 7. Patients with previous and current central nervous system (CNS)metastasis; 8. Patients with a history of hepatic encephalopathy; 9. Patients with active tuberculosis (TB), who are receiving anti-TB treatment or received anti-TB treatment within 3 months prior the first study drug administration; 10. Abdominal fistula, gastrointestinal perforation, abdominal abscess and intestinal obstruction with clinical symptoms (including occlusive disease); 11. Receipt of live or attenuated live vaccines 4 weeks prior to the first study drug treatment; 12. Suffer from any disease that requires corticosteroids within 2 weeks prior to the first study drug administration, except for local corticosteroids or dose of prednisone or equivalent drugs≤ 10mg/ day; 13. Patients with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radioactive pneumonia, drug-associated pneumonia, and severe impairment of lung function that may interfere with the detection and management of suspected drug-related lung toxicity; 14. Patients with known activity or autoimmune diseases or history. Except subjects with vitiligoare not requiring systemic treatment within 2 years prior the first study drug, type 1 diabetes mellitus, hypothyroidism requiring only hormone replacement therapy, pituitaritis and adrenal cortical insufficiency requiring only physiological hormone replacement therapy or psoriasis who do not require systemic treatment may be allowed; 15. Major surgery before enrollment or expected major surgery during the study period; 16. Severe unhealed wound, ulcers or fractures; 17. The current or recent (within 10 days before the first dose of study medication) use of aspirin for 10 days (\> 325 mg/day) or other known to inhibit platelet function of NSAIDs; a history bleeding disorders or thrombosis within 6 months before the first study drug administration; 18. Patients with clinically significant cardiovascular diseases； 19. Cardiac function: Left ventricular ejection fraction (LVEF)\<50%; 20. Human immunodeficiency virus (HIV) antibodies or acquired immune deficiency syndrome (AIDS); 21. Active hepatitis B (HBsAg positive and HBV- DNA ≥ULN) or hepatitis C (HCV antibody positive and quantitative HCV-RNA≥ULN); 22. Pregnant or lactating women during the study; 23. Patients with a history of allergy to studied drugs or similar drugs or excipients; 24. Other conditions that researchers consider inappropriate for inclusion;
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Part II: ORR(Objective Response Rate ) by investigator | 1.5 years | Proportion of subjects who have a complete or partial response relative to baseline as assessed by investigator according to RECIST 1.1 criteria |
| Part I: MTD（Maximum tolerable dose）or RD（Recommended dose） | 6 months | MTD: A maximum dose of acceptable safety, at least 6 patients treated with this dose, and less than 1/3 of patients experienced DLT(Dose limited toxicity). RD:The following will be taken into account to make decision about RD: MTD, if is reached; PK characteristics, efficacy and safety results. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PFS(Progression Free Survival) by investigator | 1.5 years | PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigator according to the RECIST1.1 criteria |
| DCR(Disease Control Rate) by investigator | 1.5 years | Proportion of subjects who have a complete or partial response, or stable disease relative to baseline as assessed by investigator according to RECIST 1.1 criteria |
| DOR(Duration Of Response) by investigator | 1.5 years | Measured from the date of partial or complete response to therapy until the disease progression based on RECIST v1.1criteria. |
| OS（Overall Survival) | 2.5 years | OS is the time interval from the date of randomization to death from any cause. |
| The incidence of AEs（adverse events) and SAEs（serious adverse events) | 2 years | Frequency and severity of Adverse Events or Serious Adverse Events as defined by CTCAE version 5.0 |
| ORR in subgroup of different TMB、PDL-1 and MSI status | 1.5 years | Proportion of subjects who have a complete or partial response relative to baseline as assessed by investigator according to RECIST 1.1 criteria in subgroup of different TMB、PDL-1 and MSI status |
Other
| Measure | Time frame | Description |
|---|---|---|
| PK(pharmacokinetics) of envofolimab and BD0801 | 1.5 years | Plasma concentrations of envofolimab an BD0801 will be measured. |
| Positive rate of ADA(anti-drug antibody) | 1.5 years | — |
| Duration of immunogenicity positive reaction | 1.5 years | — |
Countries
China
Outcome results
None listed